Overview

Pediatric Epilepsy Study in Subjects 1-24 Months

Status:
Completed

Trial end date:
2006-06-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age who have never received LAMICTAL(LAMICTAL-naive). For LAMICTAL-naive subjects, LAMICTAL will be added to the subject's current epilepsy medications.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Lamotrigine